Development of regional programs to speed treatment of stroke

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

The pathophysiology of ischemic stroke dictates that treatments be administered shortly after symptom onset to be beneficial. Intravenous tissue plasminogen activator is the only drug proven to be effective in stroke; it is approved for administration within a 3-hour window. To optimize the number of potential candidates for thrombolytic therapy, patients and families must understand the symptoms and signs of stroke and how to respond. Emergency medical services and emergency departments also must be prepared for rapid evaluation to determine if a patient is appropriate for reperfusion therapy. Due to a lack of stroke specialists in many communities, some hospitals may not be prepared to provide intravenous thrombolytic therapy around the clock, and time lost transporting patients to tertiary centers may mitigate the benefits of thrombolysis. Telestroke may be the best alternative in this scenario, extending acute stroke therapies to patients who would otherwise not receive treatment.

Original languageEnglish (US)
Pages (from-to)35-42
Number of pages8
JournalCurrent Neurology and Neuroscience Reports
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Program Development
Stroke
Thrombolytic Therapy
Therapeutics
Community Hospital
Emergency Medical Services
Tissue Plasminogen Activator
Signs and Symptoms
Reperfusion
Hospital Emergency Service
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Development of regional programs to speed treatment of stroke. / Switzer, Jeffrey A; Hess, David C.

In: Current Neurology and Neuroscience Reports, Vol. 8, No. 1, 01.01.2008, p. 35-42.

Research output: Contribution to journalReview article

@article{f5dd9ad989594980aeb6ef6f756d06f4,
title = "Development of regional programs to speed treatment of stroke",
abstract = "The pathophysiology of ischemic stroke dictates that treatments be administered shortly after symptom onset to be beneficial. Intravenous tissue plasminogen activator is the only drug proven to be effective in stroke; it is approved for administration within a 3-hour window. To optimize the number of potential candidates for thrombolytic therapy, patients and families must understand the symptoms and signs of stroke and how to respond. Emergency medical services and emergency departments also must be prepared for rapid evaluation to determine if a patient is appropriate for reperfusion therapy. Due to a lack of stroke specialists in many communities, some hospitals may not be prepared to provide intravenous thrombolytic therapy around the clock, and time lost transporting patients to tertiary centers may mitigate the benefits of thrombolysis. Telestroke may be the best alternative in this scenario, extending acute stroke therapies to patients who would otherwise not receive treatment.",
author = "Switzer, {Jeffrey A} and Hess, {David C}",
year = "2008",
month = "1",
day = "1",
doi = "10.1007/s11910-008-0007-0",
language = "English (US)",
volume = "8",
pages = "35--42",
journal = "Current Neurology and Neuroscience Reports",
issn = "1528-4042",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Development of regional programs to speed treatment of stroke

AU - Switzer, Jeffrey A

AU - Hess, David C

PY - 2008/1/1

Y1 - 2008/1/1

N2 - The pathophysiology of ischemic stroke dictates that treatments be administered shortly after symptom onset to be beneficial. Intravenous tissue plasminogen activator is the only drug proven to be effective in stroke; it is approved for administration within a 3-hour window. To optimize the number of potential candidates for thrombolytic therapy, patients and families must understand the symptoms and signs of stroke and how to respond. Emergency medical services and emergency departments also must be prepared for rapid evaluation to determine if a patient is appropriate for reperfusion therapy. Due to a lack of stroke specialists in many communities, some hospitals may not be prepared to provide intravenous thrombolytic therapy around the clock, and time lost transporting patients to tertiary centers may mitigate the benefits of thrombolysis. Telestroke may be the best alternative in this scenario, extending acute stroke therapies to patients who would otherwise not receive treatment.

AB - The pathophysiology of ischemic stroke dictates that treatments be administered shortly after symptom onset to be beneficial. Intravenous tissue plasminogen activator is the only drug proven to be effective in stroke; it is approved for administration within a 3-hour window. To optimize the number of potential candidates for thrombolytic therapy, patients and families must understand the symptoms and signs of stroke and how to respond. Emergency medical services and emergency departments also must be prepared for rapid evaluation to determine if a patient is appropriate for reperfusion therapy. Due to a lack of stroke specialists in many communities, some hospitals may not be prepared to provide intravenous thrombolytic therapy around the clock, and time lost transporting patients to tertiary centers may mitigate the benefits of thrombolysis. Telestroke may be the best alternative in this scenario, extending acute stroke therapies to patients who would otherwise not receive treatment.

UR - http://www.scopus.com/inward/record.url?scp=38649094639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649094639&partnerID=8YFLogxK

U2 - 10.1007/s11910-008-0007-0

DO - 10.1007/s11910-008-0007-0

M3 - Review article

VL - 8

SP - 35

EP - 42

JO - Current Neurology and Neuroscience Reports

JF - Current Neurology and Neuroscience Reports

SN - 1528-4042

IS - 1

ER -